Literature DB >> 18413567

Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study.

J A Driver1, T Kurth, J E Buring, J M Gaziano, G Logroscino.   

Abstract

OBJECTIVE: To evaluate the association between Parkinson disease (PD) and mortality after adjustment for comorbidities.
METHODS: We conducted a matched cohort analysis among 22,071 participants in the Physicians' Health Study. Five hundred sixty incident PD cases were identified by self-report. We used a modified Charlson Comorbidity Index to calculate a comorbidity score. Each PD case was matched by age to a comparator who was alive and had an identical comorbidity score at the time of PD diagnosis of the case. Both cohorts were followed for all-cause mortality. We used proportional hazards models to calculate hazard ratios (HRs) for mortality.
RESULTS: A total of 330 participants died over a median follow-up of 5.8 years, 200 (35.7%) in the PD group and 130 (23.2%) in the reference group. After adjustment for smoking and age at PD onset, the HR for mortality was 2.32 (95% CI 1.85-2.92). The mortality risk remained significant with increasing age at onset, even in those aged >or=80 years (HR = 2.10; 95% CI 1.44-3.00). The increased risk was apparent for short PD duration (<2 years) and remained stable with increasing duration. We found no different risk of mortality associated with PD according to smoking status.
CONCLUSIONS: In this large prospective cohort of men and after matching on comorbidities, we found that Parkinson disease patients had an increased risk of all-cause mortality. Mortality was increased regardless of disease duration, did not diminish with increasing age at onset, and was not influenced by smoking status.

Entities:  

Mesh:

Year:  2008        PMID: 18413567     DOI: 10.1212/01.wnl.0000310414.85144.ee

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  51 in total

1.  Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study.

Authors:  Julie L Kasperzyk; William V Shappley; Stacey A Kenfield; Lorelei A Mucci; Tobias Kurth; Jing Ma; Meir J Stampfer; Martin G Sanda
Journal:  J Urol       Date:  2011-09-23       Impact factor: 7.450

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

4.  Telomere length and Parkinson's disease in men: a nested case-control study.

Authors:  M Schürks; J Buring; R Dushkes; J M Gaziano; R Y L Zee; T Kurth
Journal:  Eur J Neurol       Date:  2013-09-07       Impact factor: 6.089

5.  Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Bradley F Boeve; Jonathan Graff-Radford; Walter A Rocca; Michelle M Mielke
Journal:  JAMA Neurol       Date:  2017-07-01       Impact factor: 18.302

6.  Vascular risk factors, cardiovascular disease, and restless legs syndrome in men.

Authors:  Anke C Winter; Klaus Berger; Robert J Glynn; Julie E Buring; J Michael Gaziano; Markus Schürks; Tobias Kurth
Journal:  Am J Med       Date:  2013-03       Impact factor: 4.965

7.  Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Honglei Chen; Thomas H Mosley; Alvaro Alonso; Xuemei Huang
Journal:  Am J Epidemiol       Date:  2009-03-18       Impact factor: 4.897

8.  Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.

Authors:  Markos Poulopoulos; Cheryl Waters
Journal:  Core Evid       Date:  2010-07-27

9.  Mortality and prognosis in patients with neurogenic orthostatic hypotension.

Authors:  Simona Maule; Valeria Milazzo; Milena Maria Maule; Cristina Di Stefano; Alberto Milan; Franco Veglio
Journal:  Funct Neurol       Date:  2012 Apr-Jun

10.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.